drugset / Trial / NCT05108558
Efficacy of a Novel CCH Protocol for PD Among Prior Non-responders
Phase 4
Active not recruiting
40 enrolled
Charitable Union for the Research and Education of Peyronie's Disease
RandomizedParallel-groupDouble-blindTreatment
Summary
Compare key clinical outcomes between controls and men treated with a novel CCH administration protocol among men previously unresponsive to CCH administration.
Timeline
- Start
- 2021-09-20
- Primary completion
- 2025-12-20
- Completion
- 2028-09-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Collagenase Clostridium Histolyticum | Protein / enzyme biologic | 0.9 mg | — |